C.T. Development America, Inc.

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

1 in Phase 3

Quick facts

Phase 3 pipeline

KIACTA (eprodisate disodium) · Rare Genetic Diseases / Amyloidosis
Eprodisate disodium inhibits glycosaminoglycan (GAG) synthesis and accumulation by blocking the formation of pathogenic protein-GAG complexes in amyloid-related diseases.

Phase 2 pipeline

RX-10045

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

C.T. Development America, Inc. portfolio CI brief
C.T. Development America, Inc. pipeline updates RSS